tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Stock WebsitesTop Gainers/ Losers/ Active StocksDividend StocksChatGPT Stocks
ETFs
ETF CenterTop ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Crypto CenterBitcoin
Popular
Ethereum
Research Tools
Stock ScreenerETF Screener
Popular
Compare StocksCompare ETFsTrending StocksTechnical Analysis ScreenerPenny Stock ScreenerDaily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit CalculatorCompound Interest Calculator
New
Mortgage Calculator
New
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Stock Websites
Top Gainers/ Losers/ Active Stocks
Dividend Stocks
ChatGPT Stocks
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Research Tools
Stock Screener
ETF Screener
Popular
Compare Stocks
Compare ETFs
Trending Stocks
Technical Analysis Screener
Penny Stock Screener
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compound Interest Calculator
New
Mortgage Calculator
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Enterprise Solutions
Plans & Pricing
Education
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

BIXT Stock Latest News

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
Press ReleasesBioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
11d ago
BIXT
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Press ReleasesBioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
1M ago
BIXT
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
Press ReleasesBioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
2M ago
BIXT
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
Press ReleasesBioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
3M ago
BIXT
Bioxytran Interview at the Emerging Growth Conference
Press ReleasesBioxytran Interview at the Emerging Growth Conference
6M ago
BIXT
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Press ReleasesBioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
6M ago
BIXT
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
Press ReleasesBioxytran to Appear on ClearThink IR’s Virtual Live Event
7M ago
BIXT
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
Press ReleasesBioxytran Receives Approval to Initiate Trials with ProLectin-I
8M ago
BIXT
Bioxytran Interview at the Emerging Growth Conference
Press ReleasesBioxytran Interview at the Emerging Growth Conference
8M ago
BIXT
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
Press ReleasesCrystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
9M ago
BIXT
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
Press ReleasesBioxytran Establishes Indian Subsidiary in Preparation of Commercialization
9M ago
BIXT
Bioxytran Interview at the Emerging Growth Conference
Press ReleasesBioxytran Interview at the Emerging Growth Conference
10M ago
BIXT
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
Press ReleasesBioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
10M ago
BIXT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100

More Trending Stocks >
iosandroid
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagramyoutube
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
EducationHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About usAbout TipRanksTipRanks CommunityContact UsCareersReviews
Working With TipRanksEnterprise SolutionsTop Online BrokersBecome an Affiliate
PlansPlans & PricingAPI for Institutions
Find Us on
twitterstocktwitsfacebooklinkedininstagramyoutube
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.